Merck Q2 earnings beat estimates but revenue fell short. Gardasil sales dropped while Keytruda and other treatments drove ...

The Covid-19 pandemic turned Moderna and BioNTech into household names almost overnight. Now the two companies find ...

NovoCure faces margin pressure, slow launches, and adoption hurdles beyond GBM, despite revenue beats and pipeline hopes.

By Michael Erman (Reuters) -Bristol Myers Squibb posted much better-than-expected second-quarter results on Thursday on ...

GSK’s anti-TIM monoclonal antibody (mAb) cobolimab has failed a Phase III trial in non-small cell lung cancer (NSCLC). The ...

Merck & Co – known as MSD outside of the US and Canada – has unveiled a new cost-cutting plan aimed at saving $3bn every year by the end of 2027.

In this week’s edition of InnovationRx, we look at Halle Berry’s menopause startup, Ambience Healthcare’s $243 million ...

The Federal Reserve’s Chair Jerome Powell is under immense pressure from the Trump administration to loosen the monetary ...

Maryland-based biotech NextCure is looking for partners to advance a candidate for the currently incurable rare disease ...

The abrupt exit of the former CBER director, who quickly made his mark at the agency with several high-profile and ...

Hong Kong-based CSPC will receive $120 million from Madrigal under the deal. Elsewhere, Apellis and PTC Therapeutics won FDA approvals.

Merck (MRK) announced a bold cost-cutting strategy aiming to save $3 billion annually by 2027, reflecting a major operational ...